Our succes in integrating information into models that generate unique insights, allowing executives to make better drug development decisions, is reflected in our gold-standard research publications.
Latest publications
Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients | Infectious diseases
Prohn M
et al.
|
qP contributors: Prohn M |
2021|
Journal|
Clinical Pharmacology and Therapeutics
Link
Population Pharmacokinetics of Letermovir Following Oral and Intravenous Administration in Healthy Participants and Allogeneic Hematopoietic Cell Transplantation Recipients | Infectious diseases
Prohn M
et al.
|
qP contributors: Prohn M |
2021|
Journal|
CPT: Pharmacometrics & Systems Pharmacology
Link
Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII | Haematology
Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: a semi-mechanistic autoinduction model | Oncology
Krishnatry AS
et al.
|
qP contributors: Krishnatry AS; Völkner A; Prohn M |
2021|
Journal|
CPT: Pharmacometrics & Systems Pharmacology
Link
Design and conduct considerations for studies in patients with impaired renal function | All
Ravenstijn P
et al.
|
qP contributors: Ravenstijn P |
2021|
Journal|
Clinical and Translational Science
Link
Effect of Anti-VEGF Therapy on the Disease Progression of Neovascular Age-Related Macular Degeneration: A Systematic Review and Model-Based Meta-Analysis | Ophthalmology
Exposure-response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors | Oncology
Krishnatry AS
et al.
|
qP contributors: Krishnatry AS; Hanze E; Bergsma T; Prohn M |
2021|
Journal|
CPT: Pharmacometrics & Systems Pharmacology
Link
SAGE-217: A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies | CNS
A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) With Poor Prognosis Features | Oncology
Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis | Immunology
Chan P
et al.
|
qP contributors: Prohn M, Huisman J, Matzuka B |
2020|
Journal|
Pharmaceutical Research
Link